GSK's Q3 Earnings Hit By Lower Than Expected Vaccine Sales, Cautions Lower Revenue For 2024 GSK reports Q3 sales of $10.42 billion, missing estimates due to an 18% drop in vaccine revenue, while ...

Premier Li Qiang's remarks demonstrate to the world the Chinese government's firm stance in advancing a higher level of ...

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

GSK (GSK) stock was downgraded by Guggenheim Securities to neutral after the company's Q3 revenue decline. Read more here.

Despite the rise of a vaccine skeptic in the campaign of US presidential election winner Donald Trump, GSK CEO Emma Walmsley ...

The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.

We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...